The effect of levosimendan on myocardial ischemia–reperfusion injury in streptozotocin-induced diabetic rats

References

• Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, etal. Heart disease and stroke statistics – 2011 update: a report from the American Heart Association. Circulation. 2011; 123: 1–195.
   Web of Science ®Google Scholar
• Brown JR, Edwards FH, O'Connor GT, Ross CS, Furnary AP. The diabetic disadvantage: historical outcomes measures in diabetic patients undergoing cardiac surgery – the pre-intravenous insulin era. Semin Thorac Cardiovasc Surg. 2006; 18: 281–8.
   PubMedGoogle Scholar
• Fisher BM. Heart abnormalities in IDDM. Diabetologia. 1997; 40(Suppl 2): S127–9.
   Google Scholar
• Anderson EJ, Kypson AP, Rodriguez E, Lehr EJ, Neufer PD. Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart. J Am Coll Cardiol. 2009; 54: 1891–8.
   PubMed Web of Science ®Google Scholar
• Raedschelders K, Ansley DM, Chen DD. The cellular and molecular origin of reactive oxygen species generation during myocardial ischemia and reperfusion. Pharmacol Ther. 2012; 133: 230–55.
   PubMed Web of Science ®Google Scholar
• Boudina S, Abel ED. Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord. 2010; 11: 31–9.
   PubMed Web of Science ®Google Scholar
• Hasenfuss G, Pieske B, Kretschmann B, Holubarsch C, Alpert NR, Just H. Effects of calcium sensitizers on intracellular calcium handling and myocardial energetics. J Cardiovasc Pharmacol. 1995; 26: S45–51.
   PubMed Web of Science ®Google Scholar
• Huang L, Weil MH, Tang W, Sun S, Wang J. Comparison between dobutamine and levosimendan for management of postresuscitation myocardial dysfunction. Crit Care Med. 2005; 33: 487–91.
   PubMed Web of Science ®Google Scholar
• Eriksson HI, Jalonen JR, Heikkinen LO, Kivikko M, Laine M, Leino KA, etal. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Ann Thorac Surg. 2009; 87: 448–54.
   PubMed Web of Science ®Google Scholar
• Kersten JR, Montgomery MW, Pagel PS, Warltier DC. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. Anesth Analg. 2000; 90: 5–11.
   PubMed Web of Science ®Google Scholar
• Türeci E, İş M, Üzüm G, Akyüz F, Ulu MO, Döşoğlu M, etal. Alterations in blood-brain barrier after traumatic brain injury in streptozotocin-induced diabetic rats. J Nervous Sys Surgery. 2009; 2: 79–86.
   Google Scholar
• Cakir M, Polat A, Tekin S, Vardi N, Taslidere E, Rumeysa Duran Z, etal. The effect of dexmedetomidine against oxidative and tubular damage induced by renal ischemia reperfusion in rats. Ren Fail. 2015; 37: 704–8.
   PubMed Web of Science ®Google Scholar
• Wang H, Chen H, Wang L, Liu L, Wang M, Liu X. Acute hyperglycemia prevents dexmedetomidine-induced preconditioning against renal ischemia-reperfusion injury. Acta Cir Bras. 2014; 29: 812–18.
   Web of Science ®Google Scholar
• Jeon YT, Hwang JW, Lim YJ, Park SK, Park HP. Postischemic sevoflurane offers no additional neuroprotective benefit to preischemic dexmedetomidine. J Neurosurg Anesthesiol. 2013; 25: 184–90.
   Web of Science ®Google Scholar
• Kocoglu H, Karaaslan K, Gonca E, Bozdogan O, Gulcu N. Preconditioning effects of dexmedetomidine on myocardial ischemia/reperfusion injury in rats. Curr Ther Res Clin Exp. 2008; 69: 150–8.
   PubMed Web of Science ®Google Scholar
• Loh HK, Sahoo KC, Kishore K, Ray R, Nag TC, Kumari S, etal. Effects of thalidomide on isoprenaline-induced acute myocardial injury: a haemodynamic, histopathological and ultrastructural study. Basic Clin Pharmacol Toxicol. 2007; 100: 233–9.
   Web of Science ®Google Scholar
• Asano G, Takashi E, Ishiwata T, Onda M, Yokoyama M, Naito Z, etal. Pathogenesis and protection of ischemia and reperfusion injury in myocardium. Nippon Med Sch. 2003; 70: 384–92.
   PubMedGoogle Scholar
• Ansley DM, Wang B. Oxidative stress and myocardial injury in the diabetic heart. J Pathol. 2013; 229: 232–41.
   PubMed Web of Science ®Google Scholar
• Schneider R, Welt K, Aust W, Löster H, Fitzl G. Cardiac ischemia and reperfusion in spontaneously diabetic rats with and without application of EGb 761: I. cardiomyocytes. Histol Histopathol. 2008; 23: 807–17.
   Web of Science ®Google Scholar
• Wang Y, Takashi E, Xu M, Ayub A, Ashraf M. Downregulation of protein kinase C inhibits activation of mitochondrial K (ATP) channels by diazoxide. Circulation. 2001; 104: 85–90.
   PubMed Web of Science ®Google Scholar
• Kasikcioglu HA, Cam N. A review of levosimendan in the treatment of heart failure. Vasc Health Risk Manag. 2006; 2: 389–400.
   PubMedGoogle Scholar
• Grossini E, Molinari C, Caimmi PP, Uberti F, Vacca G. Levosimendan induces NO production through p38 MAPK, ERK and Akt in porcine coronary endothelial cells: role for mitochondrial KATP channel. Br J Pharmacol. 2009; 156: 250–61.
   PubMed Web of Science ®Google Scholar
• Caimmi PP, Molinari C, Uberti F, Micalizzi E, Valente G, Mary DA, etal. Intracoronary levosimendan prevents myocardial ischemic damages and activates survival signaling through ATP-sensitive potassium channel and nitric oxide. Eur J Cardiothorac Surg. 2011; 39: e59–67.
   PubMed Web of Science ®Google Scholar
• Jefferies HJ, Virk B, Schiller B, Moran J, McIntyre CW. Frequent hemodialysis schedules are associated with reduced levels of dialysis-induced cardiac injury (myocardial stunning). Clin J Am Soc Nephrol. 2011; 6: 1326–32.
   Web of Science ®Google Scholar
• Steffens S, Montecucco F, Mach F. The inflammatory response as a target to reduce myocardial ischaemia and reperfusion injury. Thromb Haemost. 2009; 102: 240–7.
   PubMed Web of Science ®Google Scholar
• Anselmi A, Abbate A, Girola F, Nasso G, Biondi-Zoccai GG, Possati G, etal. Myocardial ischemia, stunning, inflammation, and apoptosis during cardiac surgery: a review of evidence. Eur J Cardiothorac Surg. 2004; 25: 304–11.
   Web of Science ®Google Scholar
• Wu X, Wu J, Yan X, Zhang Y. Enhancement of myocardial function and reduction of injury with levosimendan after percutaneous coronary intervention for acute myocardial infarction: a pilot study. Cardiology. 2014; 128: 202–8.
   Web of Science ®Google Scholar
• Yapici D, Altunkan Z, Ozeren M, Bilgin E, Balli E, Tamer L, etal. Effects of levosimendan on myocardial ischaemia–reperfusion injury. Eur J Anaesthesiol. 2008; 25: 8–14.
   PubMed Web of Science ®Google Scholar
• Papp JG, Pollesello P, Varro AF, Végh AS. Effect of levosimendan and milrinone on regional myocardial ischemia/reperfusion-induced arrhythmias in dogs. J Cardiovasc Pharmacol Ther. 2006; 11: 129–35.
   PubMed Web of Science ®Google Scholar
• Louhelainen M, Vahtola E, Forsten H, Merasto S, Kytö V, Finckenberg P, etal. Oral levosimendan prevents postinfarct heart failure and cardiac remodeling in diabetic Goto-Kakizaki rat. J Hypertens. 2009; 27: 2094–107.
   Web of Science ®Google Scholar